HLA Allele-Restricted Immune-Mediated Adverse Drug Reactions: Framework for Genetic Prediction
Issued Date
2022-01-06
Resource Type
eISSN
15454304
Scopus ID
2-s2.0-85123389857
Pubmed ID
34516290
Journal Title
Annual review of pharmacology and toxicology
Volume
62
Start Page
509
End Page
529
Rights Holder(s)
SCOPUS
Bibliographic Citation
Annual review of pharmacology and toxicology Vol.62 (2022) , 509-529
Suggested Citation
Jaruthamsophon K., Thomson P.J., Sukasem C., Naisbitt D.J., Pirmohamed M. HLA Allele-Restricted Immune-Mediated Adverse Drug Reactions: Framework for Genetic Prediction. Annual review of pharmacology and toxicology Vol.62 (2022) , 509-529. 529. doi:10.1146/annurev-pharmtox-052120-014115 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/86884
Title
HLA Allele-Restricted Immune-Mediated Adverse Drug Reactions: Framework for Genetic Prediction
Author's Affiliation
Other Contributor(s)
Abstract
Human leukocyte antigen (HLA) is a hallmark genetic marker for the prediction of certain immune-mediated adverse drug reactions (ADRs). Numerous basic and clinical research studies have provided the evidence base to push forward the clinical implementation of HLA testing for the prevention of such ADRs in susceptible patients. This review explores current translational progress in using HLA as a key susceptibility factor for immune ADRs and highlights gaps in our knowledge. Furthermore, relevant findings of HLA-mediated drug-specific T cell activation are covered, focusing on cellular approaches to link genetic associations to drug-HLA binding as a complementary approach to understand disease pathogenesis.